Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Faruqi & Faruqi Says It Is Investigating Potential Securities Fraud At Peregrine

RELATED NEWS
Trade PPHM now with 

National securities law firm Faruqi & Faruqi, LLP said it is investigating potential securities fraud at Peregrine Pharmaceuticals, Inc.(PPHM: Quote).

The law firm noted that the investigation focuses on whether the company and its executives violated federal securities laws by failing to disclose that: (1) there were major discrepancies between various patient sample test results and patient treatment code assignments; (2) the clinical data from the company's randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer was misleading; and (3) as a result of the foregoing, the company's positive statements about Peregrine's business, operations, and prospects, including those statements relating to the clinical data from the company's randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer lacked sufficient support.

Click here to receive FREE breaking news email alerts for Peregrine Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The terrorists, in this case, have won. In an unprecedented move that may have far-reaching cultural and political effects, Sony Pictures has scrapped the release of "The Interview." The plot of the film, a comedy starring Seth Rogen and James Franco, revolves around a fictional assassination... Here is a list of interesting stocks to watch on December 18. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed below and many more have been researched already, and... Oracle Corp. said Wednesday after the markets closed that its second quarter profit fell 2% from last year, hurt mainly by higher income tax expenses even as revenue increased 3%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.